Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II Open-Label Trial of Pazopanib Administered as a Single Agent in Patients With Unresectable or Metastatic Solitary Fibrous Tumor (SFT) and Extraskeletal Myxoid Chondrosarcoma (EMC)

NCT02066285 is registered in ClinicalTrials.gov with Grupo Espanol de Investigacion en Sarcomas as lead sponsor.

NCT NCT02066285
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02066285 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II Open-Label Trial of Pazopanib Administered as a Single Agent in Patients With Unresectable or Metastatic Solitary Fibrous Tumor (SFT) and Extraskeletal Myxoid Chondrosarcoma (EMC)
Lead sponsor
Grupo Espanol de Investigacion en Sarcomas
Phase
Phase 2
Overall status
Completed
Start date
June 30, 2014
Completion date
March 24, 2023
Enrollment
96 (actual)
Sites
7

Conditions

As the registry lists them; a condition with its own page is linked.

extraskeletal myxoid chondrosarcoma, solitary fibrous tumor